Literature DB >> 7798127

Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy.

P P Choudhary, N Thompson, R A Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7798127     DOI： 10.1007/bf00919601

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  5 in total

1.  The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system.

Authors:  H P Hartung; B Schäfer; P H van der Meide; W Fierz; K Heininger; K V Toyka
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

2.  Interferon beta in multiple sclerosis.

Authors:  B G Arnason
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

3.  Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy.

Authors:  J D Pollard; P A McCombe; J Baverstock; P A Gatenby; J G McLeod
Journal:  J Neuroimmunol       Date:  1986-12       Impact factor: 3.478

4.  Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.

Authors:  A Noronha; A Toscas; M A Jensen
Journal:  J Neuroimmunol       Date:  1993-07       Impact factor: 3.478

5.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910
  5 in total
  16 in total

1.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.

Authors:  Giovanni Pavesi; Luigi Cattaneo; Adriana Marbini; Franco Gemignani; Domenico Mancia
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

Review 4.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Inna Kleyman; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

5.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

6.  Chronic inflammatory demyelinating polyradiculoneuropathy: in a remote northern Ontario hospital.

Authors:  Taryn Taylor
Journal:  Can Fam Physician       Date:  2013-04       Impact factor: 3.275

Review 7.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

8.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

9.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 10.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.